The stock of Heron Therapeutics Inc (NASDAQ: HRTX) has increased by 4.88 when compared to last closing price of 2.15. Despite this, the company has experienced a 17.45% gain in its stock price over the last five trading sessions. zacks.com reported 2025-04-23 that Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one’s portfolio.
Is It Worth Investing in Heron Therapeutics Inc (NASDAQ: HRTX) Right Now?
Company’s 36-month beta value is 1.32.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HRTX is 150.94M, and currently, short sellers hold a 21.54% ratio of that floaft. The average trading volume of HRTX on April 23, 2025 was 1.70M shares.
HRTX’s Market Performance
The stock of Heron Therapeutics Inc (HRTX) has seen a 17.45% increase in the past week, with a -7.20% drop in the past month, and a 38.34% gain in the past quarter. The volatility ratio for the week is 6.81%, and the volatility levels for the past 30 days are at 6.99% for HRTX. The simple moving average for the last 20 days is 10.42% for HRTX stock, with a simple moving average of 14.78% for the last 200 days.
Analysts’ Opinion of HRTX
Many brokerage firms have already submitted their reports for HRTX stocks, with Rodman & Renshaw repeating the rating for HRTX by listing it as a “Buy.” The predicted price for HRTX in the upcoming period, according to Rodman & Renshaw is $7 based on the research report published on June 13, 2024 of the previous year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see HRTX reach a price target of $6. The rating they have provided for HRTX stocks is “Overweight” according to the report published on April 23rd, 2024.
Needham gave a rating of “Buy” to HRTX, setting the target price at $5 in the report published on March 13th of the previous year.
HRTX Trading at 7.88% from the 50-Day Moving Average
After a stumble in the market that brought HRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.62% of loss for the given period.
Volatility was left at 6.99%, however, over the last 30 days, the volatility rate increased by 6.81%, as shares sank -1.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.06% upper at present.
During the last 5 trading sessions, HRTX rose by +21.09%, which changed the moving average for the period of 200-days by -18.99% in comparison to the 20-day moving average, which settled at $2.05. In addition, Heron Therapeutics Inc saw 47.39% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for HRTX
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.69 for the gross margin
The net margin for Heron Therapeutics Inc stands at -0.09. The total capital return value is set at -0.08.
Based on Heron Therapeutics Inc (HRTX), the company’s capital structure generated 1.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.13.
Currently, EBITDA for the company is -5.06 million with net debt to EBITDA at -26.96. When we switch over and look at the enterprise to sales, we see a ratio of 3.2. The receivables turnover for the company is 1.95for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.29.
Conclusion
In a nutshell, Heron Therapeutics Inc (HRTX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
